Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 472 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| FT Uses quantum chemistry and AI to design novel drug molecules | $47M | Series A | Biotech | United States | Investors | |
| I IntegrantCompany profile Develops integrated solutions across artificial intelligence, medical technology and biologics Develops integrated solutions across artificial intelligence, medical technology and biologics | Undisclosed | Series A | Biotech | Australia | Investors Undisclosed | |
| FT Develops a bispecific antibody to treat anemia of inflammation | $3.5M | Seed | Biotech | Switzerland | Investors | |
| C Provides personalized health plans using causal AI and clinical expertise | $3.3M | Pre-SeedPre-seed | Biotech, Healthtech | United Kingdom | Investors | |
| Q QMatterCompany profile Develops quantum compression technology to enable computation on existing quantum and classical systems Develops quantum compression technology to enable computation on existing quantum and classical systems | $1.2M | Pre-SeedPre-seed | Biotech, Hardware | United Kingdom | Investors | |
| N NephronomicsCompany profile Develops AI-driven precision medicine for cardio-kidney-metabolic disease Develops AI-driven precision medicine for cardio-kidney-metabolic disease | Undisclosed | StrategicUndisclosed | Biotech, Healthtech | United States | Investors | |
| P PlanetaryCompany profile Fermentation infrastructure and technology licensing for producing food ingredients and bio-based materials. Fermentation infrastructure and technology licensing for producing food ingredients and bio-based materials. | CHF 22M | Series A and creditSeries A | Biotech, Foodtech | Switzerland | Investors | |
| U Develops AI-native operating system for preventive and personalized care | $9.3M | Seed | Biotech, Healthtech | United States | Investors | |
| OT Develops antiviral drugs for polyomavirus infections | $11M | Undisclosed | Biotech | United States | Investors Undisclosed | |
| S Develops AI-powered intelligent fermentation systems | $20M | StrategicUndisclosed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.